Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Change in Receivables (2020 - 2025)

Historic Change in Receivables for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $14.3 million.

  • Tarsus Pharmaceuticals' Change in Receivables rose 396108.11% to $14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.5 million, marking a year-over-year increase of 8263.23%. This contributed to the annual value of $30.1 million for FY2024, which is 8133.08% up from last year.
  • Per Tarsus Pharmaceuticals' latest filing, its Change in Receivables stood at $14.3 million for Q3 2025, which was up 396108.11% from -$4.1 million recorded in Q2 2025.
  • Tarsus Pharmaceuticals' Change in Receivables' 5-year high stood at $25.0 million during Q1 2021, with a 5-year trough of -$19.9 million in Q3 2021.
  • Moreover, its 5-year median value for Change in Receivables was $225000.0 (2022), whereas its average is $4.0 million.
  • Data for Tarsus Pharmaceuticals' Change in Receivables shows a peak YoY increase of 62510000.0% (in 2021) and a maximum YoY decrease of 1656666.67% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Tarsus Pharmaceuticals' Change in Receivables stood at -$46000.0 in 2021, then plummeted by 795.65% to -$412000.0 in 2022, then surged by 2832.77% to $11.3 million in 2023, then surged by 56.33% to $17.6 million in 2024, then dropped by 18.83% to $14.3 million in 2025.
  • Its Change in Receivables was $14.3 million in Q3 2025, compared to -$4.1 million in Q2 2025 and $15.7 million in Q1 2025.